Biothera Holding Corp. has two wholly owned subsidiaries:
Biothera Pharmaceutical Inc. is an immune oncology company. Its lead investigational drug, Imprime PGG, triggers a coordinated anti-cancer immune response and works in combination with other cancer immunotherapy drugs.
Biothera Inc. is a technology development company that possesses a large intellectual property portfolio that includes more than 140 patents and patent applications related to its immunotherapy compounds. The company is focusing its development in non-cancer immunotherapy applications.